DrugPatentWatch Database Preview

Somerset Company Profile

« Back to Dashboard

What is the competitive landscape for SOMERSET, and what generic alternatives to SOMERSET drugs are available?

SOMERSET has twelve approved drugs.

There are three US patents protecting SOMERSET drugs.

There are three patent family members on SOMERSET drugs in two countries and twelve supplementary protection certificates in eight countries.

Summary for Somerset

International Patents:	3
US Patents:	3
Tradenames:	11
Ingredients:	10
NDAs:	12
Patent Litigation for Somerset:	See patent lawsuits for Somerset

Drugs and US Patents for Somerset

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Somerset Theraps Llc	METHOCARBAMOL	methocarbamol	SOLUTION;IM-IV	207522-001	Jul 31, 2017	AP	RX	No	No
Somerset Theraps Llc	NALOXONE HYDROCHLORIDE	naloxone hydrochloride	INJECTABLE;INJECTION	207634-001	Jul 26, 2017	AP	RX	No	No
Somerset	EMSAM	selegiline	FILM, EXTENDED RELEASE;TRANSDERMAL	021336-001	Feb 27, 2006		RX	Yes	Yes	7,070,808		Y	Y
Somerset	EMSAM	selegiline	FILM, EXTENDED RELEASE;TRANSDERMAL	021336-003	Feb 27, 2006		RX	Yes	No	7,070,808		Y	Y

Expired US Patents for Somerset

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Somerset	EMSAM	selegiline	FILM, EXTENDED RELEASE;TRANSDERMAL	021336-001	Feb 27, 2006	RE34579
Somerset	EMSAM	selegiline	FILM, EXTENDED RELEASE;TRANSDERMAL	021336-001	Feb 27, 2006	7,070,808
Somerset	EMSAM	selegiline	FILM, EXTENDED RELEASE;TRANSDERMAL	021336-003	Feb 27, 2006	7,070,808
Somerset	EMSAM	selegiline	FILM, EXTENDED RELEASE;TRANSDERMAL	021336-002	Feb 27, 2006	7,638,140

Non-Orange Book US Patents for Somerset

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,846,093	Adhesive mixture for transdermal delivery of highly plasticizing drugs

International Patents for Somerset Drugs

Country	Document Number	Estimated Expiration
European Patent Office	1561461
Japan	H1160475
European Patent Office	0887075

Supplementary Protection Certificates for Somerset Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2015 00017	Denmark		PRODUCT NAME: TOBRAMYCIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/10/652/001-003 20110720
/2015	Austria		PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720
678	Luxembourg		PRODUCT NAME: TOBRAMYCINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE. FIRST REGISTRATION: 20110725
C/GB12/047	United Kingdom		PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Somerset
• Somerset Theraps Llc